Access Pharma (OTCBB: ACCP) and Michael Douglas' Cancer
Posted by Mike Sweeney on Thu, Sep 02, 2010 @ 04:28 PM
Now with the Michael Douglas' cancer story out there, ACCP's MuGard story was picked up at OTC Showcase.
"The news of Michael Douglas and his throat cancer announcement last night on “Late Night with David Letterman” is trending everywhere on the web. It was top subject on Twitter and is covering front pages of websites. On Letterman, Michael
announced that his cancer was detected three weeks ago and that it has been diagnosed as in being in “stage 4.” Mr. Douglas also stated that he just began his first round of radiation and chemotherapy as therapy.
While well-wishes, thoughts and prayers are being sent to Michael from every source that discusses the topic (and my family sends ours as well), I can’t help myself from thinking about mucositis. Perhaps I spend too many hours digging through emerging biotechnology companies and the compounds that some of them possess. Be that as it may, it is still a genuine concern of those afflicted with cancer.
Mucositis is a frequent adverse effect from chemotherapy and radiation treatments. Technically, it is defined as “the painful inflammation and ulceration of the mucous membranes lining the digestive tract.” While mucositis can appear anywhere in the gastrointestinal tract, oral mucositis specifically refers to ulcerations and/or inflammations within the mouth. There are several levels to oral mucositis, all of which can be very painful, but Grade 3 (unable to eat solid foods) and Grade 4 (unable to eat solid food or drink liquids) are particularly debilitating."
Full Story @ OTC Showcase